8:12 PM
 | 
Aug 16, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Genentech reports Phase II data for sustained delivery eye implant of ranibizumab

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said the majority of patients who received Port Delivery System (PDS) administration of ranibizumab were able to go six months or longer between implantation and the first required refill of the PDS implant in the Phase II LADDER trial to treat wet age-related macular degeneration (AMD). Data were presented at the American Society of Retina Specialists meeting in Vancouver.

The PDS is a small, refillable device that is surgically implanted...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >